Executive Summary Estonia Pharmaceuticals And Healthcare Industry SWOT Political SWOT Economic SWOT Business Environment SWOT Pharmaceutical Business Environment Ratings Table: Central And Eastern Europe Pharmaceutical Business Environment Rankings Limits Of Potential Returns Risks To Realisation Of Returns Estonia - Market Summary Regulatory Regime Recent Regulatory Developments Intellectual Property Regime Pricing Regime Reimbursement Issues Recent Pricing And Reimbursement Developments Industry Developments Epidemiology Table Occurrence Of Malignant Neoplasms In Estonia- Healthcare Sector Table: Recently Approved Generics In Estonia Healthcare Reforms Healthcare Funding Healthcare Insurance Pharmaceutical Sector Manufacturing Wholesale Sector Retail Pharmacies Table: Pharmacies And Pharmacy Market Ratios, 2004-2009 Biotechnology Medical Devices Industry Forecast Sce Overall Market Forecast Table: Estonia’s Drug Expenditure And Prescription Market Indicators, 2006-2012 (US$mn unless otherwise stated) Key Growth Factors - Industry Table: Estonia’s Health Expenditure Indicators, 2006-2012 Key Growth Factors - Macroeconomic Table: Estonia - Economic Activity Patented Market Forecast Table: Estonia’s Patented Drug Market Forecast Indicators Generics Market Forecast Table: Estonia’s Generics Market Indicators, 2006-2012 OTC Market Forecast Table: Estonia OTC Market Forecast Indicators (US$mn unless otherwise stated) Export/Import Forecasts Table: Estonia Pharmaceuticals Exports & Imports Forecasts (US$mn) Other Healthcare Data Forecasts Table: Other Healthcare Data, 2006-2012 Key Risks To our Forecast Scenario Competitive Landscape Company Monitor GlaxoSmithKline Pfizer Novartis Sanofi-Aventis Merck & Co Grindeks (includes Tallinn Pharmaceutical Plant) Our Forecast Modelling
How We Generate Our Industry Forecasts Pharmaceutical Industry Pharmaceutical Business Environment Ratings Methodology Ratings Overview Table: Pharmaceutical Business Environment Indicators Weighting Table: Weighting Of Components Sources
